SAN DIEGO, Jan. 27, 2011 /PRNewswire/ -- Profil™ Institute for Clinical Research, Inc., a company leading the industry in early phase clinical trials for diabetes and obesity, announced today that CEO Dr. Marcus Hompesch is an invited speaker at the Ramanbhai Foundation 5th International Symposium and ISCR's 4th Annual Clinical Research Conference in February.
The Ramanbhai Foundation's International Symposium will be held February 1-4 in Ahmedabad, India and is hosted by the Zydus Research Center, the research arm of Indian pharmaceutical company Zydus Cadila. The symposium's speakers include world-leading scientists from academia and the pharmaceutical industry specializing in drug research and development for cancer, inflammation, and cardio-metabolic diseases. Profil Institute's Dr. Hompesch will speak on the topic of selecting the appropriate target populations for early phase clinical research and first in human studies of diabetes drugs.
Dr. Hompesch will also present at the Indian Society for Clinical Research's (ISCR) 4th Annual Clinical Research Conference held February 11-12 at the Crowne Plaza Hotel in Gurgaon, India. The conference's focus is strengthening India's domestic clinical research industry through best practices, stricter regulatory standards and global partnerships. Dr. Hompesch will present on the topic of early clinical development in India and its proof of concept in diabetes.
"Historically India's pharmaceutical companies have focused on providing outsourcing and on competitive manufacturing of generics, APIs, and chemicals used in the manufacturing of drugs," said Dr. Marcus Hompesch, Profil Institute CEO. "However, healthcare has become a key priority for the Indian government, and we are now seeing a paradigm shift as India strives to bolster its position in the pharmaceutical and clinical research industry as a global partner, innovator and competitor."